Evaxion Biotech A/S Adr (EVAX) has released an update.
Evaxion Biotech A/S has reached a significant milestone in its Phase 2 clinical trial, with the first patient having completed the dosing regimen of the personalized cancer vaccine EVX-01, in combination with KEYTRUDA. The vaccine, developed using Evaxion’s AI-Immunology platform, has shown a favorable safety profile and is on track for a clinical efficacy readout in the third quarter of 2024. This advancement underscores Evaxion’s commitment to pioneering individualized immunotherapies for cancer treatment.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
